Research Paper Volume 15, Issue 16 pp 7974—7996

Figure 6. CXCL2 expression was upregulated in 11 types of cancer (CESC, COAD, DLBC, ESCA, GBM, KIRC, LGG, READ, STAD, THCA, UCEC), with P < 0.05 (A-1). On the other hand, CXCL2 expression was significantly (P < 0.05) downregulated in 10 types of cancer (ACC, BLCA, BLRA, KICH, HNSC, LUAD, LUSC, PAAD, PRAD, SKCM) (A-2). (B) Shows that CXCL2 was significantly (P < 0.05) associated with the survival value of 6 types of cancers (KIRC, BRCA, UVM, SARC, LUSC, ACC). The relationship between CXCL2 expression and neutrophils in various types of cancer. The correlation between CXCL2 expression and the percentage of neutrophils in pan-cancer dataset as determined by 6 different methods (C-1). CXCL2 expression in different types of cells. CXCL2 expression was highest in neutrophils (C-2). The correlation between CXCL2 expression and other CXCL genes, specifically CXCR1 and CXCR2 (C-3). The expression level of CXCL2 was positively correlated with various pro-tumor pathways in two renal cancer datasets. In the first dataset of KIRC (D-1), CXCL2 expression level was positively correlated with 6 pro-tumor pathways, including Angiogenesis, Inflammatory response, fatty acid elongation, EMT pathway, cellular response to hypoxia, and anti-inflammatory signaling pathway (P < 0.01). In the second dataset (D-2), CXCL2 expression was positively correlated with 9 key pro-tumor pathways (P < 0.01), such as apoptosis, hypoxia, P53 pathway, and glycolysis. Molecular docking analysis of CXCL2 and its receptors. Interaction models between CXCL2 and CXCR1 (E-1) and CXCR2 (E-2) were developed. These models provided insights into the molecular mechanisms behind the positive correlations between CXCL2 expression and pro-tumor pathways.